Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
Hexahydroquinoline (HHQ) scaffold was constructed and recruited for development of new
series of anticancer agents. Thirty-two new compounds were synthesised where x-ray …
series of anticancer agents. Thirty-two new compounds were synthesised where x-ray …
The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer
Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor
receptor mutant (EGFRm) advanced non-small cell lung cancer (NSCLC). Combining TKIs …
receptor mutant (EGFRm) advanced non-small cell lung cancer (NSCLC). Combining TKIs …
Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
X Jin, Y Pan, C Cheng, H Shen, C Zhai, K Yin… - Frontiers in …, 2024 - frontiersin.org
Background In individuals receiving treatment with epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience …
kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience …
[HTML][HTML] Network pharmacology and experimental validation to reveal the pharmacological mechanisms of Qizhu prescription for treating breast cancer
J Sheng, J Cheng, W Chu, M Dong, K Jiang - Journal of Traditional Chinese …, 2024 - Elsevier
Objective To investigate the mechanism underlying the effects exerted by the Qizhu
prescription (QZP) in breast cancer (BC), and the respective targets. Methods Expression …
prescription (QZP) in breast cancer (BC), and the respective targets. Methods Expression …